Last reviewed · How we verify
methylphenidate-OROS
At a glance
| Generic name | methylphenidate-OROS |
|---|---|
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Benefits of ADHD Treatment in Detained People (PHASE3)
- The Effects of ADHD Medication (TEAM) Study (PHASE4)
- Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
- The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original (NA)
- Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder
- Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 (PHASE3)
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (PHASE4)
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: